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The risk of mortality following elective total hip (THR) and knee replacements (KR) may be
influenced by patients’ pre-existing comorbidities. There are a variety of scores derived from
individual comorbidities that can be used in an attempt to quantify this. The aims of this
study were to a) identify which comorbidity score best predicts risk of mortality within 90
days or b) determine which comorbidity score best predicts risk of mortality at other relevant
timepoints (30, 45, 120 and 365 days).
Patients andmethods
We linked data from the National Joint Registry (NJR) on primary elective hip and knee
replacements performed between 2011–2015 with pre-existing conditions recorded in the
Hospital Episodes Statistics. We derived comorbidity scores (Charlson Comorbidity Index—
CCI, Elixhauser, Hospital Frailty Risk Score—HFRS). We used binary logistic regression
models of all-cause mortality within 90-days and within 30, 45, 120 and 365-days of the pri-
mary operation using, adjusted for age and gender. We compared the performance of these
models in predicting all-cause mortality using the area under the Receiver-operator charac-
teristics curve (AUROC) and the Index of Prediction Accuracy (IPA).
Results
We included 276,594 elective primary THRs and 338,287 elective primary KRs for any indi-
cation. Mortality within 90-days was 0.34% (N = 939) after THR and 0.26% (N = 865) after
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KR. The AUROC for the CCI and Elixhauser scores in models of mortality ranged from
0.78–0.81 after THR and KR, which slightly outperformed models with ASA grade (AUROC
= 0.77–0.78). HFRS performed similarly to ASA grade (AUROC = 0.76–0.78). The inclusion
of comorbidities prior to the primary operation offers no improvement beyond models with
comorbidities at the time of the primary. The discriminative ability of all prediction models
was best for mortality within 30 days and worst for mortality within 365 days.
Conclusions
Comorbidity scores add little improvement beyond simpler models with age, gender and
ASA grade for predicting mortality within one year after elective hip or knee replacement.
The additional patient-specific information required to construct comorbidity scores must be
balanced against their prediction gain when considering their utility.
Background
Elective knee (KR) and total hip (THR) replacement are amongst the most commonly per-
formed elective operations. They are also highly successful procedures with typical 10-year
revision rates of<5% [1]. Mortality after primary hip and knee replacement is rare and has
decreased in recent years [2, 3]. The National Joint Registry for England, Wales, Northern Ire-
land, the Isle of Man and the States of Guernsey (NJR) routinely monitors mortality outcomes
at surgeon and unit level. This process includes case-mix adjustment for age, gender, indica-
tion for surgery and American Society of Anaesthesiologists physical status (ASA grade) which
records the preoperative health of surgical patients.
The presence of comorbidities (pre-existing health conditions that coexist with an index
disease) is associated with worse health outcomes and more complex clinical management [4].
Comorbidity has been found to be a predictor of perioperative and in-hospital mortality [5],
and a risk factor for 90-day mortality after joint replacement [6]. The use of comorbidity score
in place of ASA grade may improve prediction of mortality risk, but collection of comorbidi-
ties is much more complex and laborious than ASA grade.
Many summary indices of comorbidities based on diagnoses have been derived, however
the main focus within replacement surgery has been on the Charlson Comorbidity (CCI) and
Elixhauser indices [7]. The Elixhauser index includes 30 conditions and is a composite mea-
surement to assess the impact of comorbidity on surgical procedures [8] and the CCI includes
17 conditions [9]. The Elixhauser index predicted inpatient mortality after orthopaedic surgery
better than the CCI [5]. However, comorbidity does not predict long-term mortality [10].
Recent developments in comorbidity scores include the Hospital Frailty Risk Score (HFRS)
[11], designed to screen for frailty and identify a group of patients who are at greater risk of
adverse outcomes. This was found to predict adverse events after THRs and KRs, but its per-
formance was not compared against other comorbidity indices [12].
The aims of this study are:
1. To determine which comorbidity score best predicts risk of mortality within 90 days of elec-
tive primary hip and knee replacement
2. To determine which comorbidity score best predicts risk of mortality within other land-
mark postoperative timepoints (30, 45, 120, 365 days) after elective primary hip and knee
replacement
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Methods
Data source
The National Joint Registry (NJR) was established in 2003 [1]. The NJR includes nearly 2.5
million primary THRs and KRs in patients aged>18 years performed in public and private
hospitals in England, Wales, Northern Ireland, the Isle of Man and the States of Guernsey [13].
Data are collected at the time of surgery on prosthesis and operative information, patient
information, and surgical and unit information. We linked these records to Hospital Episodes
Statistics (HES)–Admitted Patient Care data, established in 1989 [14], for all available episodes
up to and including the primary joint replacement operation. For people who had contralateral
primary operations we linked separate HES records for each primary operation. Date of death
was linked at the person-level using civil registration mortality records.
Ethics approval and consent to participate
Patient consent was obtained for data collection by the NJR. According to the specifications of
the NHS Health Research Authority, separate informed consent and ethical approval were not
required for the present study.
Study sample
We included patients who received a primary elective THR or KR for any indication between
January 1st 2011 and 31st December 2015. Patients were followed up until 31st December 2016.
We only included primary operations that could be linked to HES records. This excluded pri-
vately funded operations since these episodes are not recorded in HES and hence comorbidity
indices could not be derived at the time of the primary operation. This also excluded opera-
tions performed inWales and Scotland, since HES data collection only covers operations per-
formed in England. We excluded primary operations performed in Northern Ireland, the Isle
of Man and Guernsey, since data collection in these regions only commenced in 2013, 2015,
and 2020, respectively. We also excluded people who had not given consent for recording of
personal details for research purposes and primary operations performed for trauma (see Figs
1 & 2).
Potential predictors
The patient’s age at the time of surgery (in years, natural spline with knot points at 50 and 75
years) and gender (categorical) were included as potential predictors in all models and com-
prised our base model. Our reference model contained ASA grade (categorical predictor: ‘I’,
‘II’, ‘III’, ‘IV & V’), which is routinely recorded in the NJR and has the advantage of not requir-
ing linkage to other datasets. We used pre-existing conditions recorded in HES using ICD-10
codes to derive the following comorbidity scores:
• CCI with two weightings:
� Original weightings by Charlson et al. [9]: categorised ‘0’, ‘1’, ‘2’, ‘3+’
� Revised weightings developed by Dr Foster Intelligence and used by the Health and Social
Care Information Centre as part of the Summary Hospital-level Mortality Indicator
(SHMI) [15]: continuous variable
• Elixhauser comorbidity index [8]: continuous variable
• Hospital Frailty Risk Score (HFRS) [11]: continuous variable
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level Mortality Indicator; THR, Total Hip
Replacement.
We derived the comorbidity scores using pre-existing conditions recorded over the follow-
ing timeframes:
• At the time of the primary operation
• Any episodes in the 1 year up to the primary
• Any episodes in the 2 years up to the primary
• Any episodes in the 5 years up to the primary
• All available episodes up to the primary
Outcomes
All-cause mortality. Our primary outcome was mortality from all causes within 90 days
of the primary operation. Secondary outcomes were all-cause mortality within 30, 45, 120 and
365 days of the primary operation.
Fig 1. Flowchart of eligible primary THRs.
https://doi.org/10.1371/journal.pone.0255602.g001
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Statistical analysis
We analysed mortality outcomes for primary hip and knee replacements separately. We
described the comorbidity of people undergoing elective THR and KR operations. We used
predicted probabilities from logistic regression models to identify the best comorbidity predic-
tors of mortality, and the optimal timeframe over which to define the comorbidity scores. We
constructed the following regression models:
• Base model: Age and gender
• Model 1 (reference): Base + ASA
• Model 2: Base + CCI (original)
• Model 3: Base + CCI (SHMI)
• Model 4: Base + Elixhauser
• Model 5: Base + HFRS
Fig 2. Flowchart of eligible primary KRs.
https://doi.org/10.1371/journal.pone.0255602.g002
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We compared models using area under the receiver operating characteristic curve
(AUROC), a measure of how well the model discriminates between those who experience the
outcome and those who don’t (values 0 to 1, 0.5 = no discrimination, higher value = better
classifier), and the Index of Prediction Accuracy (IPA) [16], calculated from the null model
and model Brier scores to combine discrimination and calibration in a single value (values -1
to 1, 1 is a perfect model,<0 is a harmful model). We performed internal validation using
5-fold cross-validation, and reported the overall results and results of our primary analyses for
each fold.
Sensitivity analyses. Some patients received a second primary THR or KR on the opposite
joint (contralateral primary) within our follow-up timeframe. These patients will contribute
twice to our analyses. We therefore excluded the earliest performed primary and repeated our
main analyses.
Data were processed in Stata v15 (StataCorp) and all analyses were performed using R ver-
sion 4.0 [17] and the ‘tidymodels’ packages [18]. Confidence intervals (95% CI) were derived
using the exact method to evaluate the uncertainty of AUC developed by DeLong [19] and
implemented using the algorithm proposed by Sun and Xu [20] in the ‘pROC’ package [21].
Results
Our study sample was 276,594 primary THRs and 338,287 primary KRs which met the inclu-
sion criteria (Figs 1 and 2). The proportion of people who died within 90 days was 0.34%
(N = 954) after THR (Table 1) and 0.26% (N = 870) after KR (Table 2). Secondary mortality
timepoints after THR were: 30 days 0.17% (n = 465), 45 days 0.21% (n = 592), 120 days 0.43%
(n = 1,187), 365 days 1.20% (n = 3,314); and after KR were: 30 days 0.14% (n = 470), 45 days
0.17% (n = 578), 120 days 0.31% (n = 1,064), 365 days 0.91% (n = 3,085).
In patients who died within 90 days of their primary operation the five most prevalent
comorbidities from the CCI were very similar for people who had a THR or KR: COPD (THR
20%, KR 22%), diabetes without complications (THR 17%, KR 22%), renal disease (THR 16%,
KR 17%), acute myocardial infarction (THR and KR 10%) and congestive heart failure (THR
11%, KR 9.7%) (Tables 1 and 2). In the same patients, the most prevalent comorbidities from
the Elixhauser index were very similar: uncomplicated hypertension (THR 52%, KR 61%),
arrhythmia (THR 25%, KR 24%), chronic pulmonary disease (THR 20%, KR 22%), diabetes
without complications (THR 17%, KR 21%) and renal failure (THR 16%, KR 17%). There was
a marked difference in the prevalence of metastatic cancer between people who died within 90
days of their THR and KR: 12% and 0.8% respectively. This likely reflects the prophylactic
replacement of the hip in patients with metastasis in the proximal femur to prevent a femoral
fracture. Metastases in the distal femur, which may require a prophylactic knee replacement,
occur much less frequently.
A comparison of comorbidity scores derived from varying lead-up times with those derived
from all available episodes (S1–S4 Figs) highlights differences in the capture of high comorbid-
ity scores. The majority of patients had CCI score 0 and the median comorbidity score for all
measures at all time points, apart from HFRS derived using 5-year lead-up and all episodes,
was 0 (S1 Table). Increasing the timeframe for deriving comorbidity scores decreased the pro-
portion of patients with CCI = 0 and increased the comorbidity scores of the upper quartile a
modest amount and the maximum comorbidity scores considerably.
Comparison of models
1. Comorbidity indices using comorbidities at time of primary. The AUROC indicate
that, using comorbidities recorded at the time of the primary operation, the CCI (original and
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Table 1. The characteristics of people having a primary THR, including by 90-day mortality.
Characteristic Alive at 90 days Died by 90 days Total
N = 275,6401 N = 9541 N = 276,5941
Patient age at surgery 70 (62, 76) 78 (71, 83) 70 (62, 76)
Gender
Male 109,303 (40%) 501 (53%) 109,804 (40%)
Female 166,337 (60%) 453 (47%) 166,790 (60%)
ASA Grade
I 36,089 (13%) 30 (3.1%) 36,119 (13%)
II 193,934 (70%) 424 (44%) 194,358 (70%)
III 44,379 (16%) 442 (46%) 44,821 (16%)
IV +V 1,238 (0.4%) 58 (6.1%) 1,296 (0.5%)
Charlson comorbidities
Acute Myocardial Infarction 7,202 (2.6%) 95 (10.0%) 7,297 (2.6%)
Congestive heart failure 3,143 (1.1%) 108 (11%) 3,251 (1.2%)
Peripheral Vascular disease 2,931 (1.1%) 38 (4.0%) 2,969 (1.1%)
Cerebrovascular disease 1,730 (0.6%) 39 (4.1%) 1,769 (0.6%)
Dementia 1,225 (0.4%) 23 (2.4%) 1,248 (0.5%)
Chronic Obstructive Pulmonary disease 37,264 (14%) 190 (20%) 37,454 (14%)
Rheumatoid Disease 10,225 (3.7%) 46 (4.8%) 10,271 (3.7%)
Peptic Ulcer 360 (0.1%) 8 (0.8%) 368 (0.1%)
Mild liver disease 1,148 (0.4%) 12 (1.3%) 1,160 (0.4%)
Diabetes 25,860 (9.4%) 159 (17%) 26,019 (9.4%)
Diabetes + Complications 673 (0.2%) 10 (1.0%) 683 (0.2%)
Hemiplegia or Paraplegia 442 (0.2%) 10 (1.0%) 452 (0.2%)
Renal disease 12,574 (4.6%) 157 (16%) 12,731 (4.6%)
Cancer 2,951 (1.1%) 114 (12%) 3,065 (1.1%)
Moderate/Severe liver disease 90 (<0.1%) 5 (0.5%) 95 (<0.1%)
Metastatic Cancer 671 (0.2%) 113 (12%) 784 (0.3%)
AIDS 0 (0%) 0 (0%) 0 (0%)
Elixhauser comorbidities
Congestive Heart Failure 3,143 (1.1%) 108 (11%) 3,251 (1.2%)
Cardiac Arrhythmias 21,695 (7.9%) 241 (25%) 21,936 (7.9%)
Valvular Disease 5,739 (2.1%) 62 (6.5%) 5,801 (2.1%)
Pulmonary Circulation Disorders 719 (0.3%) 32 (3.4%) 751 (0.3%)
Peripheral Vascular Disorders 2,931 (1.1%) 38 (4.0%) 2,969 (1.1%)
Hypertension, Uncomplicated 124,027 (45%) 496 (52%) 124,523 (45%)
Paralysis 442 (0.2%) 10 (1.0%) 452 (0.2%)
Other Neurological Disorders 4,311 (1.6%) 33 (3.5%) 4,344 (1.6%)
Chronic Pulmonary Disease 37,264 (14%) 190 (20%) 37,454 (14%)
Diabetes, Uncomplicated 25,840 (9.4%) 159 (17%) 25,999 (9.4%)
Diabetes, Complicated 686 (0.2%) 10 (1.0%) 696 (0.3%)
Hypothyroidism 18,948 (6.9%) 54 (5.7%) 19,002 (6.9%)
Renal Failure 12,567 (4.6%) 156 (16%) 12,723 (4.6%)
Liver Disease 1,172 (0.4%) 20 (2.1%) 1,192 (0.4%)
Peptic Ulcer Disease Excluding Bleeding 322 (0.1%) 3 (0.3%) 325 (0.1%)
AIDS/HIV 0 (0%) 0 (0%) 0 (0%)
Lymphoma 459 (0.2%) 7 (0.7%) 466 (0.2%)
Metastatic Cancer 671 (0.2%) 113 (12%) 784 (0.3%)
(Continued)
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SHMI, AUROCTHR = 0.80 and AUROCKR = 0.78) and Elixhauser scores (AUROCTHR = 0.81
and AUROCKR = 0.78) slightly outperformed ASA grade (AUROCTHR = 0.78 and AUROCKR
= 0.77) in predicting 90-day mortality after THR and KR (Table 3 and Figs 3 and 4). HFRS per-
formed similarly to ASA grade in predicting 90-day mortality after THR and KR (AUROCTHR
= 0.77, AUROCKR = 0.78). All models performed better than the base model (age and gender
only, AUROCTHR = 0.72, AUROCKR = 0.74). IPA scores for all models with comorbidity pre-
dictors recorded at the time of the primary were comparable or higher than models with ASA
grade for THRs (IPA = 0.66% to 2.1% versus IPA = 0. 67%) and KRs (IPA = 0.51% to 1.0% ver-
sus IPA = 0.56%) and higher than those for the base models (IPATHR = 0.36%, IPAKR =
0.38%). ROC curves using comorbidity scores derived from conditions recorded at the time of
the primary are shown in Figs 5 and 6.
2. Comorbidity indices using history of comorbidities. There was little difference
between the discriminative abilities of comorbidity scores derived over different timeframes.
The AUROC varied by a maximum of 1/10thof a percentage point (Table 3). ROC curves for
all timeframes are shown in S5–S12 Figs. IPA scores for all models with comorbidity predictors
were highest when derived using comorbidities recorded at the time of the primary compared
with those which were derived longer timeframes (Table 3). IPA scores for the CCI (original)
and Elixhauser index were lowest when all available episodes were included, whereas IPA
scores for CCI (SHMI) and HFRS were lowest when two to five years of preceding episodes
were used to derive the scores.
3. Landmarks. For all comorbidity scores the performance of the prediction models after
THR and KR was best for the shortest timeframe (30 days) and their performance worsened
with increasing time (Table 4). For THAs, CCI (original and SHMI) and Elixhauser had mar-
ginally better discriminative ability than ASA. HFRS had better discriminative ability than
ASA for mortality by 30 and 45 days, but was slightly worse for mortality by 120 and 365 days.
For KRs, there was almost no difference in the discriminative ability of models with ASA
grade compared with any comorbidity score, irrespective of the mortality timeframe. IPA
scores increased with increasing time for all potential predictors, indicating improved accuracy
for mortality predictions at one year compared with 30 days.
Table 1. (Continued)
Characteristic Alive at 90 days Died by 90 days Total
N = 275,6401 N = 9541 N = 276,5941
Solid Tumor Without Metastasis 2,095 (0.8%) 102 (11%) 2,197 (0.8%)
Rheumatoid Arthritis/Collagen Vascular 12,020 (4.4%) 51 (5.3%) 12,071 (4.4%)
Coagulopathy 1,052 (0.4%) 11 (1.2%) 1,063 (0.4%)
Obesity 27,689 (10%) 68 (7.1%) 27,757 (10%)
Weight Loss 103 (<0.1%) 1 (0.1%) 104 (<0.1%)
Fluid and Electrolyte Disorders 3,724 (1.4%) 110 (12%) 3,834 (1.4%)
Blood Loss Anemia 104 (<0.1%) 1 (0.1%) 105 (<0.1%)
Deficiency Anemia 2,127 (0.8%) 15 (1.6%) 2,142 (0.8%)
Alcohol Abuse 5,065 (1.8%) 24 (2.5%) 5,089 (1.8%)
Drug Abuse 314 (0.1%) 2 (0.2%) 316 (0.1%)
Psychoses 382 (0.1%) 7 (0.7%) 389 (0.1%)
Depression 10,862 (3.9%) 36 (3.8%) 10,898 (3.9%)
Hypertension, Complicated 1,228 (0.4%) 17 (1.8%) 1,245 (0.5%)
1Median (IQR); n (%).
https://doi.org/10.1371/journal.pone.0255602.t001
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Table 2. The characteristics of people having a primary KR, including by 90-day mortality.
Characteristic Alive at 90 days Died by 90 days Total
N = 337,4171 N = 8701 N = 338,2871
Patient age at surgery 69 (63, 76) 78 (72, 83) 69 (63, 76)
Gender
Male 144,609 (43%) 485 (56%) 145,094 (43%)
Female 192,808 (57%) 385 (44%) 193,193 (57%)
ASA Grade
I 31,924 (9.5%) 23 (2.6%) 31,947 (9.4%)
II 249,274 (74%) 485 (56%) 249,759 (74%)
III 55,227 (16%) 335 (39%) 55,562 (16%)
IV +V 992 (0.3%) 27 (3.1%) 1,019 (0.3%)
Charlson comorbidities
Acute Myocardial Infarction 8,494 (2.5%) 91 (10%) 8,585 (2.5%)
Congestive heart failure 3,099 (0.9%) 84 (9.7%) 3,183 (0.9%)
Peripheral Vascular disease 3,199 (0.9%) 33 (3.8%) 3,232 (1.0%)
Cerebrovascular disease 2,171 (0.6%) 38 (4.4%) 2,209 (0.7%)
Dementia 1,123 (0.3%) 14 (1.6%) 1,137 (0.3%)
Chronic Obstructive Pulmonary disease 49,782 (15%) 189 (22%) 49,971 (15%)
Rheumatoid Disease 14,822 (4.4%) 62 (7.1%) 14,884 (4.4%)
Peptic Ulcer 539 (0.2%) 7 (0.8%) 546 (0.2%)
Mild liver disease 1,269 (0.4%) 14 (1.6%) 1,283 (0.4%)
Diabetes 43,851 (13%) 184 (21%) 44,035 (13%)
Diabetes + Complications 1,060 (0.3%) 8 (0.9%) 1,068 (0.3%)
Hemiplegia or Paraplegia 536 (0.2%) 7 (0.8%) 543 (0.2%)
Renal disease 15,030 (4.5%) 149 (17%) 15,179 (4.5%)
Cancer 2,877 (0.9%) 18 (2.1%) 2,895 (0.9%)
Moderate/Severe liver disease 67 (<0.1%) 9 (1.0%) 76 (<0.1%)
Metastatic Cancer 224 (<0.1%) 7 (0.8%) 231 (<0.1%)
AIDS 0 (0%) 0 (0%) 0 (0%)
Elixhauser comorbidities
Congestive Heart Failure 3,099 (0.9%) 84 (9.7%) 3,183 (0.9%)
Cardiac Arrhythmias 25,624 (7.6%) 205 (24%) 25,829 (7.6%)
Valvular Disease 6,108 (1.8%) 57 (6.6%) 6,165 (1.8%)
Pulmonary Circulation Disorders 1,318 (0.4%) 27 (3.1%) 1,345 (0.4%)
Peripheral Vascular Disorders 3,199 (0.9%) 33 (3.8%) 3,232 (1.0%)
Hypertension, Uncomplicated 172,530 (51%) 534 (61%) 173,064 (51%)
Paralysis 536 (0.2%) 7 (0.8%) 543 (0.2%)
Other Neurological Disorders 6,277 (1.9%) 28 (3.2%) 6,305 (1.9%)
Chronic Pulmonary Disease 49,782 (15%) 189 (22%) 49,971 (15%)
Diabetes, Uncomplicated 43,806 (13%) 184 (21%) 43,990 (13%)
Diabetes, Complicated 1,098 (0.3%) 8 (0.9%) 1,106 (0.3%)
Hypothyroidism 25,139 (7.5%) 59 (6.8%) 25,198 (7.4%)
Renal Failure 15,023 (4.5%) 149 (17%) 15,172 (4.5%)
Liver Disease 1,301 (0.4%) 20 (2.3%) 1,321 (0.4%)
Peptic Ulcer Disease Excluding Bleeding 494 (0.1%) 3 (0.3%) 497 (0.1%)
AIDS/HIV 0 (0%) 0 (0%) 0 (0%)
Lymphoma 374 (0.1%) 3 (0.3%) 377 (0.1%)
Metastatic Cancer 224 (<0.1%) 7 (0.8%) 231 (<0.1%)
Solid Tumor Without Metastasis 2,071 (0.6%) 14 (1.6%) 2,085 (0.6%)
Rheumatoid Arthritis/Collagen Vascular 16,361 (4.8%) 66 (7.6%) 16,427 (4.9%)
Coagulopathy 1,254 (0.4%) 14 (1.6%) 1,268 (0.4%)
(Continued)
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Table 2. (Continued)
Characteristic Alive at 90 days Died by 90 days Total
N = 337,4171 N = 8701 N = 338,2871
Obesity 48,727 (14%) 80 (9.2%) 48,807 (14%)
Weight Loss 40 (<0.1%) 2 (0.2%) 42 (<0.1%)
Fluid and Electrolyte Disorders 4,449 (1.3%) 87 (10%) 4,536 (1.3%)
Blood Loss Anemia 73 (<0.1%) 2 (0.2%) 75 (<0.1%)
Deficiency Anemia 2,723 (0.8%) 18 (2.1%) 2,741 (0.8%)
Alcohol Abuse 5,606 (1.7%) 18 (2.1%) 5,624 (1.7%)
Drug Abuse 177 (<0.1%) 1 (0.1%) 178 (<0.1%)
Psychoses 362 (0.1%) 2 (0.2%) 364 (0.1%)
Depression 13,918 (4.1%) 33 (3.8%) 13,951 (4.1%)
Hypertension, Complicated 1,571 (0.5%) 22 (2.5%) 1,593 (0.5%)
1Median (IQR); n (%).
https://doi.org/10.1371/journal.pone.0255602.t002
Table 3. The area under the ROC curve and IPA for ASA grade and all comorbidity scores for models of 90-day mortality after THR and KR, adjusted for age and
gender.
Model THRs KRs
AUROC1 95% CI2 IPA3 AUROC1 95% CI2 IPA3
Base 0.720 0.703–0.737 0.0036 0.744 0.727–0.761 0.0038
ASA 0.775 0.760–0.791 0.0067 0.766 0.750–0.782 0.0056
CCI (original)
Primary episode 0.802 0.788–0.816 0.0087 0.775 0.759–0.792 0.0069
1-year lead-up 0.801 0.787–0.815 0.0082 0.775 0.759–0.792 0.0065
2-year lead-up 0.803 0.789–0.817 0.0082 0.776 0.760–0.792 0.0062
5-year lead-up 0.799 0.785–0.812 0.0074 0.774 0.758–0.791 0.0062
All episodes 0.792 0.778–0.806 0.0070 0.774 0.757–0.790 0.0057
CCI (SHMI)
Primary episode 0.802 0.788–0.817 0.0088 0.781 0.765–0.797 0.0098
1-year lead-up 0.799 0.785–0.814 0.0060 0.780 0.764–0.797 0.0088
2-year lead-up 0.799 0.784–0.813 0.0053 0.779 0.763–0.795 0.0070
5-year lead-up 0.792 0.777–0.806 0.0059 0.780 0.764–0.796 0.0074
All episodes 0.786 0.771–0.800 0.0060 0.778 0.762–0.794 0.0071
Elixhauser
Primary episode 0.808 0.794–0.823 0.0214 0.779 0.762–0.795 0.0103
1-year lead-up 0.810 0.796–0.825 0.0141 0.779 0.762–0.795 0.0085
2-year lead-up 0.815 0.802–0.829 0.0099 0.780 0.764–0.796 0.0074
5-year lead-up 0.814 0.801–0.828 0.0080 0.778 0.761–0.794 0.0068
All episodes 0.810 0.796–0.824 0.0078 0.774 0.758–0.791 0.0062
Frailty
Primary episode 0.765 0.748–0.782 0.0066 0.777 0.760–0.793 0.0051
1-year lead-up 0.769 0.753–0.786 0.0034 0.775 0.759–0.792 0.0024
2-year lead-up 0.769 0.753–0.785 0.0027 0.775 0.758–0.791 0.0018
5-year lead-up 0.766 0.750–0.783 0.0026 0.773 0.756–0.790 0.0028
All episodes 0.763 0.747–0.780 0.0036 0.771 0.755–0.788 0.0033
1 –AUROC–area under the ROC curve.
2–95% CI– 95% confidence intervals.
3 –IPA–Index of Prediction Accuracy.
https://doi.org/10.1371/journal.pone.0255602.t003
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Sensitivity analyses
The results from the five-fold cross-validation show variability of approximately five to seven
percentage points in the AUCTHR and approximately two and four percentage points in the
AUCKR between the best and worst performing folds (S4 and S5 Tables). IPA scores varied
considerably, including with two of the five folds indicating harmful models (negative IPA
scores).
We excluded 12,723 contralateral THRs and 20,703 contralateral KRs performed within
one year of the corresponding first primary operation. Results of our primary analyses changed
by only 0.3 percentage points (results not reported).
Discussion
We compared the performance of four comorbidity scores (CCI with original and SHMI
weights, Elixhauser Index and HFRS) in predicting the risk of all-cause mortality within 30,
Fig 3. Area under the ROC curves (higher better, lines represent 95% CIs) and IPA scores (higher better) for models of
90-day mortality after THR with ASA grade and the 4 comorbidity indices for all time frames, including age and gender.
https://doi.org/10.1371/journal.pone.0255602.g003
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45, 90, 120 and 365 days of primary elective THRs and KRs. We found that mortality predic-
tions from models with comorbidity scores add only a modest improvement compared with
those from models with ASA grade. The CCI (original and SHMI) and Elixhauser scores all
performed slightly better than ASA grade in predicting mortality after THR. The inclusion of
comorbidities either at the time of or prior to the primary operation offers little improvement
beyond models with ASA grade in the prediction of the risk of dying up to one year.
The main strengths of this study relate to the size and completeness of the NJR dataset, and
the HES linkage. Mortality within 90 days of elective hip or knee replacement is a rare event
and remains so up to one year after the primary operation. The size of the NJR meant that we
were able to use a more recent dataset and not rely on the outcomes of operations performed
early in the NJR which may not reflect the current postoperative mortality trends, while still
having sufficient events to be confident in our findings. The completeness of the NJR data is
high. A recent NJR audit of procedure recording compliance found capture rates were 95.7%
for primary procedures [22]. This reduces the likelihood of differential reporting which may
Fig 4. Area under the ROC curves (higher better, lines represent 95% CIs) and IPA scores (higher better) for models of
90-day mortality after KR with ASA grade and the 4 comorbidity indices for all time frames, including age and gender.
https://doi.org/10.1371/journal.pone.0255602.g004
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have affected our models. Our ability to link with the HES data enabled us to derive four differ-
ent comorbidity indices from the underlying ICD-10 codes and could potentially facilitate the
derivation of more comorbidity scores in future.
The need for linkage to HES to derive comorbidity indices is also an important limitation
of this study. The availability of HES data for linkage is variable, particularly for privately
funded hospital episodes. Therefore, we were not able to derive comorbidity scores for many
of the people who had privately funded joint replacements. These patients may have had fewer
comorbidities, since private sector units tend to treat patients with fewer comorbidities than
publicly funded units [23], although this may not have affected our findings. A further weak-
ness of the HES data is that we do not know whether all pre-existing conditions are recorded
for each episode, whether they are recorded accurately or whether incentives to report comor-
bidities have changed over time. A comparison of comorbidities recorded through HES with
those from primary care records (clinical practice research database, CPRD) found that CPRD
recorded more comorbidity than HES, but this did not adversely affect their models of mortal-
ity risk after gastrointestinal bleeding or diabetes [24]. This suggests that our HES records are
likely to be missing some comorbidities, but these may not be important for modelling mortal-
ity risk. Some of the conditions recorded at the time of the primary operation may have been
conditions which were not present on admission (i.e. complications) [25]. Our models of the
risk of mortality may be missing important predictors. This study focussed on assessing
whether comorbidity scores should be used instead of ASA grade in existing models, rather
Fig 5. ROC curves for models of 90-day mortality after THR with base model, ASA grade and the 4 comorbidity indices derived
using conditions recorded at the time of the primary, including age and gender.
https://doi.org/10.1371/journal.pone.0255602.g005
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than building more comprehensive models to predict these outcomes. In future it may be valu-
able to consider which other variables should be included in these models. We treated some of
the comorbidity scores as continuous variables and alternative parameterisations may be use-
ful, however categorisation of continuous variables rarely increases the ability to detect differ-
ences. Although completeness of the NJR and linked mortality data are high, we do not know
how many patients have missing dates of death, which may occur for example if someone emi-
grates after their primary operation. Given the study population and short follow-up time this
is unlikely to change our main findings. Finally, we did not validate our models using an exter-
nal dataset. This would be essential if we intended to develop new prediction models to be
applied to new patients, but this is outside the scope of our study.
The performance of our models including CCI and Elixhauser indices (AUROC = 0.78–
0.81) predicted 90-day mortality slightly worse than those by Menendez et al.
(AUROC = 0.83–0.86) [5] and are comparable with those by Inacio et al. (AUCTHR = 0.79–
0.80, AUCKR = 0.77) [7]. The timeframe for deriving comorbidity made little difference to
model performance. The modest improvements in model fit, which is consistent with Bülow
et al. [10], suggest that conditions recorded at the time of the primary joint replacement opera-
tion are likely sufficient for capturing comorbidities related to post-operative mortality.
Our models predicted earlier mortality risk better than one-year mortality risk. This is
unsurprising given that ASA Grade, CCI and Elixhauser index were derived to better inform
risk of death or adverse events during or immediately after surgery. Bülow et al. [10] found
Fig 6. ROC curves for models of 90-day mortality after KR with the base model, ASA grade and the 4 comorbidity indices derived
using conditions recorded at the time of the primary, including age and gender.
https://doi.org/10.1371/journal.pone.0255602.g006
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that, while comorbidity score (Elixhauser or Charlson) on its own was a poor predictor of
mortality risk 5–14 years after primary THR, the performance of models which included age
and gender was comparable with those for our much shorter time frame (AUROC = 0.74–
0.76). This indicates that the decrease in discriminative ability we observed for models of
365-day mortality compared with 30-day mortality may plateau for risk of mortality beyond
one year.
This research has confirmed, using a very large national dataset with very good coverage
and completeness, that there is little advantage to using comorbidity scores rather than ASA
grade to predict risk of mortality within one year of elective hip and knee replacement. Future
Table 4. The area under the ROC curve and IPA for ASA grade and all comorbidity scores for models of 30, 45, 90, 120 and 365-day mortality after THR and KR,
adjusted for age and gender.
Model THRs KRs
AUROC1 95% CI2 IPA3 AUROC1 95% CI2 IPA3
Base
30 days 0.761 0.739–0.783 0.0029 0.756 0.733–0.779 0.0023
45 days 0.739 0.719–0.760 0.0029 0.747 0.726–0.768 0.0026
120 days 0.713 0.698–0.729 0.0042 0.741 0.726–0.756 0.0043
365 days 0.708 0.699–0.717 0.0095 0.735 0.726–0.744 0.0103
ASA
30 days 0.795 0.774–0.817 0.0038 0.771 0.749–0.793 0.0031
45 days 0.781 0.761–0.800 0.0040 0.763 0.742–0.784 0.0037
120 days 0.773 0.759–0.786 0.0078 0.763 0.748–0.778 0.0064
365 days 0.755 0.746–0.763 0.0175 0.756 0.747–0.764 0.0142
CCI (original)
30 days 0.817 0.797–0.837 0.0060 0.785 0.763–0.807 0.0049
45 days 0.810 0.792–0.827 0.0062 0.776 0.755–0.796 0.0052
120 days 0.798 0.786–0.811 0.0098 0.772 0.757–0.786 0.0075
365 days 0.770 0.762–0.778 0.0179 0.758 0.750–0.767 0.0142
CCI (SHMI)
30 days 0.820 0.800–0.840 0.0056 0.793 0.771–0.814 0.0081
45 days 0.813 0.794–0.831 0.0066 0.783 0.763–0.804 0.0085
120 days 0.798 0.785–0.811 0.0096 0.777 0.763–0.792 0.0107
365 days 0.768 0.760–0.776 0.0189 0.760 0.751–0.768 0.0166
Elixhauser
30 days 0.828 0.808–0.848 0.0139 0.791 0.770–0.813 0.0071
45 days 0.822 0.804–0.840 0.0151 0.783 0.762–0.803 0.0078
120 days 0.803 0.790–0.816 0.0212 0.778 0.763–0.793 0.0112
365 days 0.770 0.762–0.779 0.0296 0.758 0.750–0.767 0.0181
Frailty
30 days 0.808 0.786–0.829 0.0032 0.794 0.772–0.817 0.0003
45 days 0.792 0.772–0.812 0.0032 0.786 0.765–0.807 0.0009
120 days 0.756 0.741–0.772 0.0074 0.772 0.756–0.787 0.0080
365 days 0.731 0.722–0.740 0.0167 0.749 0.741–0.758 0.0148
All comorbidity scores were derived using conditions recorded at the time of the primary operation.
1 –AUROC–area under the ROC curve.
2–95% CI– 95% confidence intervals.
3 –IPA–Index of Prediction Accuracy.
https://doi.org/10.1371/journal.pone.0255602.t004
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research may explore whether these models can be improved by using other algorithms in
addition to logit models, particularly for very rare outcomes such as mortality after elective
replacement. However, logit models are generally considered to be robust and perform well.
Although we have used the comorbidity indices as they have been used in many other studies,
the additive approach used to combine conditions in the CCI is algebraically incorrect [26]
and Elixhauser et al. intended the comorbidities to be retained as independent measures rather
than used to derive a summary Elixhauser index [8]. It may therefore be valuable to explore
the impact of these accepted but incorrect approaches may have on mortality prediction.
Finally, it may be beneficial to investigate whether comorbidity scores or specific comorbid
conditions predict risk of revision after joint replacement surgery.
Conclusions
The comorbidity scores used in this study offered little to no improvements over ASA grade in
models of mortality between 30 and 365 days after elective hip or knee replacement surgery. If
ASA grade is already available and linkage between datasets is needed to derive comorbidity
scores, the inability to link some operations and the additional technical and administrative
burdens of including comorbidity scores in models of mortality are not justified.
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